# Aurora Cannabis Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Aurora Cannabis Inc). ## Overview Aurora Cannabis Inc. is a Canadian cannabis company focused on medical cannabis products and related patient supply services. It operates across Canada, Europe, Australia, and New Zealand, with manufacturing and distribution assets that support regulated medical markets. ## Products & services • Medical cannabis flower and dried cannabis • Cannabis oils and extracts • GMP-certified medical cannabis manufacturing • Medical cannabis brand portfolio • Import, distribution, and pharmacy supply services - **Medical cannabis flower** (45%) — Cultivated cannabis products sold into regulated medical markets. - **Cannabis oils and extracts** (20%) — Processed cannabinoid products used by medical patients and dispensary channels. - **Branded medical cannabis** (20%) — Portfolio products sold under Aurora, MedReleaf, Pedanios, IndiMed, San Raf, and Whistler. - **Distribution and pharmacy services** (15%) — Import, distribution, and virtual pharmacy services supporting patient delivery. - Medical cannabis flower and dried cannabis - Cannabis oils and extracts - GMP-certified medical cannabis manufacturing - Medical cannabis brand portfolio - Import, distribution, and pharmacy supply services ## Customers Aurora sells primarily to medical cannabis patients through regulated distribution, pharmacy, and healthcare channels. It also serves medical market intermediaries such as importers, distributors, and licensed pharmacies in countries where the product is dispensed under strict regulatory controls. - **Medical cannabis patients** (primary) — Patients buying prescribed or authorized cannabis products for therapeutic use. - **Licensed pharmacies** (primary) — Pharmacies sourcing regulated cannabis for patient dispensing and fulfillment. - **Import and distribution partners** (secondary) — Channel partners that move product through country-specific regulatory systems. - **International medical market operators** (secondary) — Businesses buying compliant cannabis supply for regulated overseas markets. - Medical cannabis patients seeking physician-directed treatment - Licensed pharmacies dispensing medical cannabis products - Importers and distributors serving regulated markets - Healthcare channels requiring GMP-compliant supply - International market partners in Europe and Oceania ## Geography Aurora's business spans Canada, Europe, Australia, and New Zealand, with medical cannabis sales tied to regulated country-by-country market access. The company also has GMP-certified manufacturing in Canada and Germany and uses UK-based distribution and pharmacy assets to reach patients more directly. - **Canada** (0%) — No authoritative revenue-by-geography table was provided. - **Europe** (0%) — No authoritative revenue-by-geography table was provided. - **Australia and New Zealand** (0%) — No authoritative revenue-by-geography table was provided. - Canada is a core manufacturing and operating base - Germany supports GMP-certified production for Europe - The UK is an important medical cannabis distribution market - Australia and New Zealand are served as regulated export markets - Country-specific rules shape product access and channel structure ## Strategy Aurora's strategy centers on regulated medical cannabis markets where product quality, GMP certification, and supply chain control matter. It is expanding direct control of distribution and pharmacy access in key markets such as the UK while using its brand portfolio and manufacturing footprint to support international growth. - **Strengthen UK medical cannabis distribution** (short-term) — Direct ownership of import, distribution, and pharmacy assets improves control over patient supply and channel economics. - **Use GMP-certified manufacturing as a differentiator** (medium-term) — Regulated markets often require high compliance standards, so certified production supports access and trust. - **Broaden international medical market reach** (medium-term) — Diversifying across multiple medical cannabis markets reduces reliance on any single jurisdiction. - Expand in regulated medical cannabis markets - Use GMP certification as a market-access advantage - Increase direct control of distribution and pharmacy channels - Leverage branded product portfolio across regions - Support international growth through manufacturing assets ## Risks Aurora's business depends on regulated medical cannabis markets, so licensing, import rules, and product compliance can affect access to customers and supply chains. Geographic concentration in country-specific medical channels creates execution risk, while cannabis remains an industry with regulatory uncertainty, pricing pressure, and quality-control requirements. - **Regulatory and licensing dependence** [high] — Medical cannabis sales require country-specific approvals, import permissions, and pharmacy distribution rules. - **Supply chain and compliance disruption** [high] — The business relies on GMP-certified cultivation, processing, import, and last-mile delivery to patients. - **Market concentration in regulated medical channels** [medium] — Revenue depends on a relatively limited set of medical cannabis markets and channel partners. - **Cannabis industry pricing pressure** [medium] — Competition and market maturation can compress pricing in medical cannabis categories. - Regulatory changes can restrict product access or distribution - Country-level licensing risk affects market entry and continuity - Quality and GMP compliance failures could disrupt sales - Cross-border supply chains create customs and logistics risk - Medical cannabis demand and pricing can vary by jurisdiction ## Accounting Aurora's results are shaped by inventory valuation, biological/cultivation-related estimates, and the timing of revenue recognition when product moves through regulated supply chains. Medical cannabis businesses also face judgment around provisions, impairments, and non-GAAP measures such as adjusted EBITDA and working capital, which can change how operating performance is viewed. - **Inventory valuation** — Gross margin and inventory write-down risk - **Revenue recognition** — Quarterly revenue timing - **Impairment of intangibles and facilities** — Non-cash charges and book value - **Non-GAAP adjusted EBITDA** — Comparability with GAAP earnings - Inventory valuation affects margins if product costs or obsolescence change - Revenue recognition depends on when control passes to regulated buyers - Biological asset and cultivation estimates can affect reported results - Impairment testing matters for brands, facilities, and acquired assets - Working capital and adjusted EBITDA are important non-GAAP indicators --- *Last updated: 2026-09-28T11:57:34.469450+00:00*